Impaired ceramide signalling in spontaneously hypertensive rat vascular smooth muscle

A possible mechanism for augmented cell proliferation

Douglas G. Johns, R Clinton Webb, John R. Charpie

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objectives: In hypertension, the vascular wall undergoes morphological changes that alter mechanical responses to vasoactive substances. Ceramide is a recently identified second messenger synthesized in response to cytokines such as tumour necrosis factor α (TNF-α). It has been previously demonstrated that vascular smooth muscle cells (VSMC) from genetically hypertensive rats proliferate at a higher rate than those of normotensive origin. We tested the hypothesis that the ceramide pathway is impaired in VSMC from spontaneously hypertensive rats (SHR). Design: VSMC were isolated from aortae of SHR and from Wistar-Kyoto (WKY) rats. Ceramide levels were measured under baseline and agonist-stimulated conditions and cell proliferation was monitored. Methods: Cell proliferation was determined by cell counting. Ceramide levels were determined via radioactive labelling, high-performance thin-layer chromatography and phosphorimaging. Relative mRNA levels of neutral sphingomyelinase were determined using semiquantitative polymerase chain reaction (PCR). Results: Basal ceramide levels in untreated cells were lower in cells from SHR compared to WKY rats. During chronic treatment with TNF-α, ceramide levels increased in WKY rat cells but remained unchanged in cells from SHR. TNF-α treatment had an inhibitory effect on WKY rat VSMC proliferation, but stimulated proliferation in cells from SHR. Short-term incubation with TNF-α resulted in a greater increase in ceramide in cells from WKY rats than those from SHR. Semiquantitative PCR analysis indicated that neutral sphingomyelinase mRNA may be reduced in SHR VSMC. Conclusions: We conclude that ceramide synthesis is impaired in vascular smooth muscle from SHR and may contribute to increased VSMC proliferation in hypertension.

Original languageEnglish (US)
Pages (from-to)63-70
Number of pages8
JournalJournal of hypertension
Volume19
Issue number1
DOIs
StatePublished - Feb 6 2001

Fingerprint

Ceramides
Inbred SHR Rats
Vascular Smooth Muscle
Cell Proliferation
Inbred WKY Rats
Smooth Muscle Myocytes
Tumor Necrosis Factor-alpha
Sphingomyelin Phosphodiesterase
Hypertension
Polymerase Chain Reaction
Messenger RNA
Second Messenger Systems
Thin Layer Chromatography
Blood Vessels
Aorta
Cytokines

Keywords

  • Ceramide
  • Cultured vascular smooth muscle
  • Sphingomyelinase
  • Spontaneously hypertensive rats

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Impaired ceramide signalling in spontaneously hypertensive rat vascular smooth muscle : A possible mechanism for augmented cell proliferation. / Johns, Douglas G.; Webb, R Clinton; Charpie, John R.

In: Journal of hypertension, Vol. 19, No. 1, 06.02.2001, p. 63-70.

Research output: Contribution to journalArticle

@article{7db0bd10ca064940b8fb10783a9dbd93,
title = "Impaired ceramide signalling in spontaneously hypertensive rat vascular smooth muscle: A possible mechanism for augmented cell proliferation",
abstract = "Objectives: In hypertension, the vascular wall undergoes morphological changes that alter mechanical responses to vasoactive substances. Ceramide is a recently identified second messenger synthesized in response to cytokines such as tumour necrosis factor α (TNF-α). It has been previously demonstrated that vascular smooth muscle cells (VSMC) from genetically hypertensive rats proliferate at a higher rate than those of normotensive origin. We tested the hypothesis that the ceramide pathway is impaired in VSMC from spontaneously hypertensive rats (SHR). Design: VSMC were isolated from aortae of SHR and from Wistar-Kyoto (WKY) rats. Ceramide levels were measured under baseline and agonist-stimulated conditions and cell proliferation was monitored. Methods: Cell proliferation was determined by cell counting. Ceramide levels were determined via radioactive labelling, high-performance thin-layer chromatography and phosphorimaging. Relative mRNA levels of neutral sphingomyelinase were determined using semiquantitative polymerase chain reaction (PCR). Results: Basal ceramide levels in untreated cells were lower in cells from SHR compared to WKY rats. During chronic treatment with TNF-α, ceramide levels increased in WKY rat cells but remained unchanged in cells from SHR. TNF-α treatment had an inhibitory effect on WKY rat VSMC proliferation, but stimulated proliferation in cells from SHR. Short-term incubation with TNF-α resulted in a greater increase in ceramide in cells from WKY rats than those from SHR. Semiquantitative PCR analysis indicated that neutral sphingomyelinase mRNA may be reduced in SHR VSMC. Conclusions: We conclude that ceramide synthesis is impaired in vascular smooth muscle from SHR and may contribute to increased VSMC proliferation in hypertension.",
keywords = "Ceramide, Cultured vascular smooth muscle, Sphingomyelinase, Spontaneously hypertensive rats",
author = "Johns, {Douglas G.} and Webb, {R Clinton} and Charpie, {John R.}",
year = "2001",
month = "2",
day = "6",
doi = "10.1097/00004872-200101000-00009",
language = "English (US)",
volume = "19",
pages = "63--70",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Impaired ceramide signalling in spontaneously hypertensive rat vascular smooth muscle

T2 - A possible mechanism for augmented cell proliferation

AU - Johns, Douglas G.

AU - Webb, R Clinton

AU - Charpie, John R.

PY - 2001/2/6

Y1 - 2001/2/6

N2 - Objectives: In hypertension, the vascular wall undergoes morphological changes that alter mechanical responses to vasoactive substances. Ceramide is a recently identified second messenger synthesized in response to cytokines such as tumour necrosis factor α (TNF-α). It has been previously demonstrated that vascular smooth muscle cells (VSMC) from genetically hypertensive rats proliferate at a higher rate than those of normotensive origin. We tested the hypothesis that the ceramide pathway is impaired in VSMC from spontaneously hypertensive rats (SHR). Design: VSMC were isolated from aortae of SHR and from Wistar-Kyoto (WKY) rats. Ceramide levels were measured under baseline and agonist-stimulated conditions and cell proliferation was monitored. Methods: Cell proliferation was determined by cell counting. Ceramide levels were determined via radioactive labelling, high-performance thin-layer chromatography and phosphorimaging. Relative mRNA levels of neutral sphingomyelinase were determined using semiquantitative polymerase chain reaction (PCR). Results: Basal ceramide levels in untreated cells were lower in cells from SHR compared to WKY rats. During chronic treatment with TNF-α, ceramide levels increased in WKY rat cells but remained unchanged in cells from SHR. TNF-α treatment had an inhibitory effect on WKY rat VSMC proliferation, but stimulated proliferation in cells from SHR. Short-term incubation with TNF-α resulted in a greater increase in ceramide in cells from WKY rats than those from SHR. Semiquantitative PCR analysis indicated that neutral sphingomyelinase mRNA may be reduced in SHR VSMC. Conclusions: We conclude that ceramide synthesis is impaired in vascular smooth muscle from SHR and may contribute to increased VSMC proliferation in hypertension.

AB - Objectives: In hypertension, the vascular wall undergoes morphological changes that alter mechanical responses to vasoactive substances. Ceramide is a recently identified second messenger synthesized in response to cytokines such as tumour necrosis factor α (TNF-α). It has been previously demonstrated that vascular smooth muscle cells (VSMC) from genetically hypertensive rats proliferate at a higher rate than those of normotensive origin. We tested the hypothesis that the ceramide pathway is impaired in VSMC from spontaneously hypertensive rats (SHR). Design: VSMC were isolated from aortae of SHR and from Wistar-Kyoto (WKY) rats. Ceramide levels were measured under baseline and agonist-stimulated conditions and cell proliferation was monitored. Methods: Cell proliferation was determined by cell counting. Ceramide levels were determined via radioactive labelling, high-performance thin-layer chromatography and phosphorimaging. Relative mRNA levels of neutral sphingomyelinase were determined using semiquantitative polymerase chain reaction (PCR). Results: Basal ceramide levels in untreated cells were lower in cells from SHR compared to WKY rats. During chronic treatment with TNF-α, ceramide levels increased in WKY rat cells but remained unchanged in cells from SHR. TNF-α treatment had an inhibitory effect on WKY rat VSMC proliferation, but stimulated proliferation in cells from SHR. Short-term incubation with TNF-α resulted in a greater increase in ceramide in cells from WKY rats than those from SHR. Semiquantitative PCR analysis indicated that neutral sphingomyelinase mRNA may be reduced in SHR VSMC. Conclusions: We conclude that ceramide synthesis is impaired in vascular smooth muscle from SHR and may contribute to increased VSMC proliferation in hypertension.

KW - Ceramide

KW - Cultured vascular smooth muscle

KW - Sphingomyelinase

KW - Spontaneously hypertensive rats

UR - http://www.scopus.com/inward/record.url?scp=0035139720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035139720&partnerID=8YFLogxK

U2 - 10.1097/00004872-200101000-00009

DO - 10.1097/00004872-200101000-00009

M3 - Article

VL - 19

SP - 63

EP - 70

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 1

ER -